At a glance
ClinicalIndex Comparison RecordN/ACompleted· 186,394 enrolled
Drug / intervention
5ARIdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
5 Alpha Reductase Inhibitors And The Risk Of Suicide And Depression
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·observational·Posted Aug 24, 2016·Updated Jan 12, 2024
In Brief
An observational study evaluating 5ARI for BPH and 2 related conditions. Completed, enrolled 186,394 participants.
Detailed Summary
In December 2015, Health Canada issued a warning about a potential relationship between suicide and finasteride use and called for further research. No population based studies have assessed the risk of suicide with finasteride use, and this risk is not currently part of the product monograph. Furthermore, the link between depression and finasteride has not been well studied in the older population who are the primary users of this medication.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBPH, Depression, Suicide
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2003
Primary CompletionDec 2013
First PostedAug 2016
Study CompletionMar 2017
TodayJul 2026
First PostedAug 24, 2016
Enrollment StartJan 1, 2003
Primary CompletionDec 1, 2013
Study CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 10.9 yearsPosted 9.9 years ago
Interventions
5ARIdrug
Exposure to finasteride/dutasteride